Study #2023-0171
Phase I/II trial of cord blood-derived NK cells genetically engineered with NY-ESO-1 TCR/IL-15 cell receptor for Relapsed/Refractory Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK
Description
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloma
Study phase:
Physician name:
Jing Ye
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-925-1217
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.